Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids
A phase 2 trial of Patient-derived organoids in Non-muscle-invasive bladder cancer, run by Hospital Centre Biel/Bienne, not yet recruiting.
Overview
Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids is a phase 2 interventional study registered as NCT06227065 by Hospital Centre Biel/Bienne, with 28 participants planned, started 2026-12-01 and due to reach its primary completion in 2030-11-30. Interventions recorded: Epirubicin, Mitomycin, Gemcitabine, Docetaxel. Conditions recorded: Bladder Cancer, Non-muscle Invasive Bladder Cancer, Low Grade.
Linked to the technology Patient-derived organoids because the registry's title names it ("patient derived organoids") and Non-muscle-invasive bladder cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC
Shares Non-muscle-invasive bladder cancer, Docetaxel, Gemcitabine and the tag pipeline.
- TrialA Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Shares Non-muscle-invasive bladder cancer, Docetaxel, Gemcitabine and the tag pipeline.
- TrialSafety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer
Shares Epirubicin, Docetaxel and the tag pipeline.
- TrialA Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Shares Non-muscle-invasive bladder cancer, Gemcitabine and the tag pipeline.
- TrialSequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer
Shares Epirubicin, Docetaxel and the tag pipeline.
- TrialRandomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer
Shares Epirubicin, Docetaxel and the tag pipeline.
- TrialSix vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer
Shares Epirubicin, Docetaxel and the tag pipeline.
- TrialIntravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Shares Non-muscle-invasive bladder cancer and the tag pipeline.